Lung Cancer
Conditions
Brief summary
Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade. Primary endpoint: Estimate 1-year- and 5-year-mortality rates in patients with PLC. Secondary endpoints: * Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020 * Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies * Estimate prognostic factors * Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies * Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies
Interventions
None listed
Sponsors
Collège des Pneumologues des Hôpitaux Généraux
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age ≥ 18 years * Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\* * Follow-up by a lung specialist at a General Hospital * Oral informed consent \* date of collected sample
Exclusion criteria
* Age \< 18 years * Secondary lung cancer * Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery * Previous enrolment in the study * Freedom deprived patient following a legal or administrative decision * Patient unable to give his(her) consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate 1-year mortality rates in patients with PLC. | 1 year | Global survival at 1 year |
| Estimate 5-year mortality rates in patients with PLC. | 5 years | Global survival at 5 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies | 1 year | \- Disease data: diagnostic method, anatomopathological classification, PDL-1 status, molecular biology test, tumor mutation burden, TNM classification, and stage (8th edition) |
| Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020 | 1 year | \- Patient data: age, gender, birth location, height, weight, comorbidity score, smoking status, cannabis uptake, Performance Status, and death |
Countries
France
Outcome results
None listed